Citius Non Operating Income Net Other from 2010 to 2024

CTXR Stock  USD 3.32  0.28  7.78%   
Citius Pharmaceuticals Non Operating Income Net Other yearly trend continues to be relatively stable with very little volatility. Non Operating Income Net Other is likely to drop to about 303.9 K. During the period from 2010 to 2024, Citius Pharmaceuticals Non Operating Income Net Other destribution of quarterly values had r-value of  0.18 from its regression line and median of  332,095. View All Fundamentals
 
Non Operating Income Net Other  
First Reported
2011-06-30
Previous Quarter
29.6 K
Current Value
53 K
Quarterly Volatility
385.3 K
 
Yuan Drop
 
Covid
Check Citius Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Citius Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 234.6 K, Interest Expense of 303.6 K or Selling General Administrative of 26.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 26.01. Citius financial statements analysis is a perfect complement when working with Citius Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Citius Pharmaceuticals Correlation against competitors.
To learn how to invest in Citius Stock, please use our How to Invest in Citius Pharmaceuticals guide.

Latest Citius Pharmaceuticals' Non Operating Income Net Other Growth Pattern

Below is the plot of the Non Operating Income Net Other of Citius Pharmaceuticals over the last few years. It is Citius Pharmaceuticals' Non Operating Income Net Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Citius Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Non Operating Income Net Other10 Years Trend
Pretty Stable
   Non Operating Income Net Other   
       Timeline  

Citius Non Operating Income Net Other Regression Statistics

Arithmetic Mean340,265
Coefficient Of Variation123.89
Mean Deviation227,379
Median332,095
Standard Deviation421,561
Sample Variance177.7B
Range2.1M
R-Value0.18
Mean Square Error185.3B
R-Squared0.03
Significance0.53
Slope16,739
Total Sum of Squares2.5T

Citius Non Operating Income Net Other History

2024303.9 K
2023561.5 K
2020488.3 K
2019178.3 K
201852.7 K
20171.3 M
2016452.1 K

About Citius Pharmaceuticals Financial Statements

Citius Pharmaceuticals shareholders use historical fundamental indicators, such as Non Operating Income Net Other, to determine how well the company is positioned to perform in the future. Although Citius Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Citius Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Citius Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Non Operating Income Net Other561.5 K303.9 K

Pair Trading with Citius Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Citius Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Citius Stock

  0.71HLN Haleon plcPairCorr
  0.71JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
  0.74PFE Pfizer Inc Aggressive PushPairCorr
  0.68ANRO Alto Neuroscience,PairCorr

Moving against Citius Stock

  0.82AXP American Express Fiscal Year End 24th of January 2025 PairCorr
  0.75TRV The Travelers Companies Fiscal Year End 17th of January 2025 PairCorr
  0.69FNMFO Federal National Mortgage Upward RallyPairCorr
  0.67KB KB Financial GroupPairCorr
  0.62ITCL Banco Ita ChilePairCorr
The ability to find closely correlated positions to Citius Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Citius Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Citius Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Citius Pharmaceuticals to buy it.
The correlation of Citius Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Citius Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Citius Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Citius Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Citius Stock Analysis

When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.